sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells and augments chemotherapeutics in vivo. Here, we developed sTRAIL-iRGD, a recombinant protein consisting of sTRAIL fused to CRGDKGPDC, a C-terminal end binding peptide with an integrin-binding arginine-glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ying, Li, Xihan, Sha, Huizi, Zhang, Lianru, Bian, Xinyu, Han, Xiao, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428854/
https://www.ncbi.nlm.nih.gov/pubmed/28373646
http://dx.doi.org/10.1038/s41598-017-00688-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428854/
https://www.ncbi.nlm.nih.gov/pubmed/28373646
http://dx.doi.org/10.1038/s41598-017-00688-6

Ejemplares similares